PAXIL CR Drug Patent Profile

When do Paxil Cr patents expire, and what generic alternatives are available?

Paxil Cr is a drug marketed by Apotex and is included in one NDA.

The generic ingredient in PAXIL CR is paroxetine hydrochloride. There are thirty drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the paroxetine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Paxil Cr

A generic version of PAXIL CR was approved as paroxetine hydrochloride by APOTEX on July 30^th, 2003.

Summary for PAXIL CR

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	80
Patent Applications:	1,114
Drug Prices:	Drug price information for PAXIL CR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PAXIL CR
DailyMed Link:	PAXIL CR at DailyMed

See drug prices for PAXIL CR

See drug sales revenues for PAXIL CR

Pharmacology for PAXIL CR

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Paragraph IV (Patent) Challenges for PAXIL CR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PAXIL CR	Extended-release Tablets	paroxetine hydrochloride	37.5 mg	020936	1	2009-05-19
PAXIL CR	Extended-release Tablets	paroxetine hydrochloride	25 mg	020936	1	2005-09-09

US Patents and Regulatory Information for PAXIL CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-001	Feb 16, 1999	AB	RX	Yes	No
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-002	Feb 16, 1999	AB	RX	Yes	No
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-003	Dec 6, 2000	AB	RX	Yes	Yes

Expired US Patents for PAXIL CR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-002	Feb 16, 1999
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-002	Feb 16, 1999
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-003	Dec 6, 2000
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-001	Feb 16, 1999
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-001	Feb 16, 1999
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-001	Feb 16, 1999
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-002	Feb 16, 1999

International Patents for PAXIL CR

See the table below for patents covering PAXIL CR around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1020464
United Kingdom	9914601
Turkey	200100055
South Korea	100289885
Portugal	102384
Czech Republic	297171	Anhydrát paroxetin-hydrochloridu, zpusob jeho prípravy, farmaceutický prostredek s jeho obsahem a pouzití (Paroxetine-hydrochloride anhydrate, process for its preparation, and pharmaceutical composition in which the anhydrate is comprised and use thereof)
European Patent Office	1020464

Market Dynamics and Financial Trajectory for PAXIL CR: An In-Depth Analysis

Last updated: January 1, 2026

Executive Summary

PAXIL CR (paroxetine controlled-release) is a widely prescribed selective serotonin reuptake inhibitor (SSRI) manufactured by GlaxoSmithKline (GSK). Introduced in 2001, it has served as a prominent treatment for depression, generalized anxiety disorder, obsessive-compulsive disorder, and social anxiety disorder. Despite facing intense generic competition post-patent expiration, PAXIL CR maintains a significant presence in the psychopharmacology market due to brand loyalty, formulary inclusion, and its differentiated controlled-release formulation. This analysis explores the product's market dynamics, revenue trajectory, competitive landscape, regulatory factors, and future outlook, providing a detailed view of its current and projected financial performance.

---

1. Market Overview and Historical Context

1.1 Product Introduction and Patent Timeline

Year	Milestone	Details
2001	Launch of PAXIL CR	First-approved controlled-release version of paroxetine in the U.S.
2004	Patent Expiry in key markets	Patents protecting PAXIL CR's formulation expired in the U.S. and Europe, opening the door to generics.

1.2 Therapeutic Indications

• Major Depressive Disorder (MDD)
• Generalized Anxiety Disorder (GAD)
• Obsessive-Compulsive Disorder (OCD)
• Social Anxiety Disorder (SAD)
• Panic Disorder

1.3 Market Share & Pre-Generic Era Performance

Pre-2010, PAXIL CR commanded significant market share, driven by its innovative controlled-release technology and brand reputation:

Year	Estimated Global Sales (USD millions)	Market Share (Prescription Volume)
2005	~$600	~10% of SSRI market
2010	~$650	~8%

---

2. Market Dynamics Post-Patent Expiry

2.1 Patent Expiration and Generic Competition

The expiration of patents in 2004/2005 led to a surge in generic paroxetine sales. GSK strategically maintained a branded segment via PAXIL CR's proprietary formulation, which was challenging for generics to replicate exactly.

Patent Expiration Year	Impact on Sales	Generic Market Entry
2004	Rapid decline in branded sales due to generics	Yes

2.2 Impact Analysis

Year	Estimated US Sales (USD millions)	Proportion of Generics (%)	Remarks
2004	~$400	60%	Shift toward generics
2008	<$200	85%	Dominance of generics, brand retention largely in niche segments
2012	<$50	>90%	PAXIL CR's market presence greatly diminished

2.3 Strategy for Brand Preservation

GSK focused on:

• Maintaining a differentiated formulation (controlled-release mechanism).
• Building strong formulary positions (especially in managed care settings).
• Promoting off-patent PAXIL in select markets with limited generic penetration.
• Launching PAXIL shortly before patent expiry to maximize revenue.

---

3. Current Market Landscape & Revenue Trajectory

3.1 Present Market Position

Despite the rise of cheap generics, PAXIL CR retains niche yet stable sales, especially in specific patient populations and regions. Its controlled-release profile offers advantages such as reduced dosing frequency and improved adherence.

3.2 Revenue Breakdown (Recent Data)

Region	2021 Revenue (USD millions)	Market Share (Estimated)	Remarks
US	~$30	Limited (~2%-3%)	Niche therapeutic preference
Europe	~$10	Low (~1%)	Competition from generics
Rest of World	~$15	Low (~1%-2%)	Growing markets, still brand-dependent
Total	~USD 55 million	-

3.3 Key Factors Influencing Revenue

• Continued generic erosion in major markets.
• Physician and patient loyalty to brand for specific formulations.
• Pricing strategies, including premium pricing for controlled-release benefits.
• Reimbursement policies and formulary placement.

---

4. Competitive Landscape and Market Forces

4.1 Competitor Analysis

Competitor	Product	Formulation	Market Position & Notes
Generic Paroxetine	Paroxetine (generic)	Immediate-release	Cost-driven, dominant post-patent expiry
Brand SSRIs (e.g., Prozac)	Fluoxetine	Immediate-release	Competes for similar indications, different profile
Novel Drugs	Esketamine, Vortioxetine	Various	Indirect competition for treatment-resistant depression

4.2 Pricing and Reimbursement Dynamics

Factor	Impact on Revenue
Price erosion from generic competition	Significant downward pressure
Managed care formulary decisions	Limited access for generics, favoring branded formulations
Reimbursement policies	Variations across countries; influence adoption

4.3 Regulatory and Policy Considerations

• Patent cliffs and biosimilar/biodrug policies influence market dynamics.
• FDA and EMA approvals of generics and biosimilars can accelerate loss of exclusivity.
• EU and US policies encouraging biosimilar use may indirectly affect parity products like PAXIL CR.

---

5. Financial Projections and Future Outlook

5.1 Revenue Forecasting Scenarios

Scenario	Key Assumptions	Estimated 2023-2025 Revenue (USD millions)	Notes
Conservative	Continued generic erosion; limited brand loyalty	~$20-$30 per year	Focused on niche markets, minimal growth
Optimistic	Successful brand differentiation, expanding indications	~$40-$50 per year	Potential repositioning or label expansion
Pessimistic	Accelerated generic penetration, regulatory barriers	<$20 per year	Market exit or further decline

5.2 Key Drivers for Future Growth or Decline

• Growth Drivers: Niche indications, new formulations, market expansion.
• Decline Factors: Pricing pressures, patent expiry, availability of alternative therapies.

5.3 Strategic Recommendations

• Focus on patient adherence and personalized medicine to maintain niche positioning.
• Explore formulation innovations like sustained-release or combination therapies.
• Strengthen formulary placements via clinical evidence promotion.
• Pursue lifecycle management and label extension opportunities, including off-label uses.

---

6. Comparative Analysis: PAXIL CR vs. Other SSRIs

Parameter	PAXIL CR	Prozac (Fluoxetine)	Zoloft (Sertraline)
Patent Status	Expired (2004/2005)	Expired	Expired
Formulation Type	Controlled-release	Immediate-release	Immediate-release
Market Niche	Niche adherence benefits	Broad market	Broad market
Pricing Strategy	Premium for controlled-release	Competitive	Competitive

---

7. Key Regulatory and Patent-Related Policies

Regulation/Policy	Effect on PAXIL CR Market	Source/Authority
Patent Law (US & EU)	Defines patent expiry, generic entry timing	USPTO, EPO
Hatch-Waxman Act (US)	Facilitates generic approval, impacts brand exclusivity	FDA
Biosimilar Policies	May influence perceptions of branded SSRIs	FDA, EMA

---

8. FAQs

Q1: How does PAXIL CR differentiate from generic paroxetine formulations?
A1: PAXIL CR offers a controlled-release mechanism providing once-daily dosing and potentially improved compliance, which generics with immediate-release formulations lack. This differentiation helps maintain niche loyalty despite patent expiration.

Q2: What factors limit the growth of PAXIL CR in current markets?
A2: Increased availability of low-cost generics, pricing pressures, and shifting prescribing patterns favor newer or alternative medications.

Q3: Are there developments suggesting a renewed market for PAXIL CR?
A3: While no recent patents or blockbuster indications are expected, continued research into specific patient populations or formulations may create minor opportunities.

Q4: How does the competitive landscape affect PAXIL CR’s profitability?
A4: Intensified generic competition reduces revenue margins, leading to reduced profitability unless offset by brand loyalty or premium features.

Q5: What is the outlook for PAXIL CR in emerging markets?
A5: Growing healthcare infrastructure and demand for established antidepressants offer some opportunities, though cost sensitivity remains a barrier.

---

Key Takeaways

• Patent expiration in 2004/2005 led to a sharp decline in PAXIL CR’s market share in major markets, with generics dominating the landscape.
• Differentiated formulation remains its primary competitive edge, enabling niche positioning despite low sales volumes.
• Revenue remains stable in select markets through formulary strategies, brand loyalty, and clinical positioning.
• Competitive pressures and regulatory changes continue to favor generics, constraining growth prospects.
• Future outlook hinges on lifecycle management, innovative formulations, and expanding into emerging markets with tailored strategies.

---

References

[1] GlaxoSmithKline. (2022). PAXIL CR product details and patents.
[2] IQVIA. (2022). Global Pharmaco-economic Data.
[3] FDA. (2021). Approved Drug Products with Therapeutic Equivalence Evaluations.
[4] European Medicines Agency. (2022). Marketing authorization for PAXIL CR.
[5] PhRMA. (2020). Patent cliffs and biosimilar policies.